The consistency of the amyloid cascade hypothesis has been recently discussed elsewhere [105,106], and within this framework, our main point is neither to discuss the idea that Aβ accumulation is the primary trigger for other pathogenetic events, such as hyperphosphorylated tau and dementia, nor to examine whether Aβ is the major target for the development of AD therapy. This evidence concerns the gene MAPT and Alzheimer disease.